Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Colin Baigent Clear advanced filters

  • The ankle–brachial index (ABI) can be used to assess the risk of cardiovascular events. The AAA trial aimed to determine whether low-dose aspirin was of net benefit among apparently healthy people with an ABI ≤0.95. The largely negative findings of this study raise important mechanistic and practical questions.

    • Carlo Patrono
    • Colin Baigent
    News & Views
    Nature Reviews Cardiology
    Volume: 7, P: 306-307

  • The Women's Health Study seemed to contradict evidence from randomized trials of aspirin by identifying a sex-related difference in response to aspirin in cardiovascular disease. In this Viewpoint Hennekens et al. discuss the findings and argue that concluding that there are sex-related differences in response to aspirin could be premature.

    • Charles H Hennekens
    • Danielle Hollar
    • Colin Baigent
    Reviews
    Nature Clinical Practice Cardiovascular Medicine
    Volume: 3, P: 4-5

  • The role of aspirin for the primary prevention of cardiovascular disease is controversial. In this Review, Patrono and Baigent discuss the new randomized trials on aspirin for the primary prevention of cardiovascular disease in the context of previous evidence, and appraise whether the new evidence is likely to enable a more targeted use of aspirin

    • Carlo Patrono
    • Colin Baigent
    Reviews
    Nature Reviews Cardiology
    Volume: 16, P: 675-686

  • The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed.

    • David Preiss
    • Colin Baigent
    News & Views
    Nature Reviews Nephrology
    Volume: 13, P: 450-451

  • The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.

    • Charles H. Hennekens
    • Colin Baigent
    News & Views
    Nature Reviews Cardiology
    Volume: 9, P: 262-263

  • A meta-analysis of individual-level patient data from 66 clinical studies supports the utility of glomerular filtration rate as a surrogate endpoint in clinical trials for chronic kidney disease, with potential to enable detection of events earlier in the disease course.

    • Lesley A. Inker
    • Willem Collier
    • Mauro Saddelli
    Research
    Nature Medicine
    Volume: 29, P: 1867-1876